GEP20146102B - Compounds and compositions as protein kinase inhibitors - Google Patents
Compounds and compositions as protein kinase inhibitorsInfo
- Publication number
- GEP20146102B GEP20146102B GEAP201012645A GEAP2010012645A GEP20146102B GE P20146102 B GEP20146102 B GE P20146102B GE AP201012645 A GEAP201012645 A GE AP201012645A GE AP2010012645 A GEAP2010012645 A GE AP2010012645A GE P20146102 B GEP20146102 B GE P20146102B
- Authority
- GE
- Georgia
- Prior art keywords
- compositions
- compounds
- protein kinase
- kinase inhibitors
- basis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23807309P | 2009-08-28 | 2009-08-28 | |
| US31303910P | 2010-03-11 | 2010-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20146102B true GEP20146102B (en) | 2014-05-27 |
Family
ID=42782253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201012645A GEP20146102B (en) | 2009-08-28 | 2010-08-27 | Compounds and compositions as protein kinase inhibitors |
Country Status (49)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| US8907270B2 (en) | 2010-06-30 | 2014-12-09 | Schlumberger Technology Corporation | Method and apparatus for gain regulation in a gamma detector |
| BR112014011223A8 (pt) * | 2011-11-11 | 2023-01-31 | Novartis Ag | Método de tratar uma doença proliferativa |
| MX353446B (es) | 2011-11-23 | 2018-01-12 | Novartis Ag | Formulaciones farmaceuticas. |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| WO2013096642A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9629839B2 (en) | 2012-03-28 | 2017-04-25 | Dana-Farber Cancer Institute, Inc. | C-RAF mutants that confer resistance to RAF inhibitors |
| CN104640857B (zh) | 2012-07-18 | 2017-07-04 | 圣路易斯大学 | 作为整合素拮抗剂的β氨基酸衍生物 |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| SG11201500321YA (en) * | 2012-08-07 | 2015-04-29 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| HK1206605A1 (en) | 2012-08-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| US20150232452A1 (en) * | 2012-09-19 | 2015-08-20 | Ruga Corporation | Novel raf kinase inhibitors |
| CA2890663A1 (en) | 2012-11-08 | 2014-05-15 | Novartis Ag | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| EP2976106B1 (en) * | 2013-03-21 | 2021-04-14 | Array BioPharma Inc. | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
| TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
| BR112015028845A2 (pt) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| BR112016014481B1 (pt) * | 2013-12-20 | 2022-11-08 | Biomed Valley Discoveries, Inc | Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit |
| AU2014372166B2 (en) * | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| DE102015103158A1 (de) | 2014-03-04 | 2015-09-10 | Bergische Universität Wuppertal | Verbindungen für die Behandlung des Melanoms |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| EP3143166A4 (en) * | 2014-05-16 | 2018-04-18 | University of Massachusetts | Treating chronic myelogenous leukemia (cml) |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| EP3191478B1 (en) * | 2014-09-12 | 2019-05-08 | Novartis AG | Compounds and compositions as raf kinase inhibitors |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| MY198562A (en) | 2015-11-03 | 2023-09-05 | Janssen Biotech Inc | Antibodies specifically binding pd-1 and their uses |
| JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子およびその使用 |
| HK1244806A1 (zh) | 2015-12-30 | 2018-08-17 | Saint Louis University | 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物 |
| RU2615986C1 (ru) * | 2016-02-25 | 2017-04-12 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения |
| BR112018074941A2 (pt) * | 2016-06-03 | 2019-03-12 | Caponigro Giordano | combinações farmacêuticas |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CA3048376A1 (en) * | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
| WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107540699A (zh) * | 2017-10-16 | 2018-01-05 | 康化（上海）新药研发有限公司 | 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法 |
| US11725185B2 (en) | 2017-12-28 | 2023-08-15 | University Of Houston System | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12076320B2 (en) | 2018-07-12 | 2024-09-03 | Shenzhen Targetrx, Inc. | Diarylpyrazole compound, composition comprising same, and use thereof |
| WO2020124397A1 (en) | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| EP3968995A1 (en) | 2019-05-16 | 2022-03-23 | Eli Lilly and Company | Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer |
| WO2021110997A1 (en) | 2019-12-05 | 2021-06-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors |
| US12303509B2 (en) | 2020-06-09 | 2025-05-20 | Pfizer Inc. | Compounds for the treatment of BRAF-associated diseases and disorders |
| EP4196228A1 (en) | 2020-08-13 | 2023-06-21 | Albert Einstein College of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
| MX2023003867A (es) | 2020-10-05 | 2023-04-18 | Pf Medicament | Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. |
| WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN117642166A (zh) | 2021-06-09 | 2024-03-01 | 中外制药株式会社 | 用于癌症治疗的组合疗法 |
| CN114557977A (zh) * | 2022-02-16 | 2022-05-31 | 北京康立生医药技术开发有限公司 | 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024163166A1 (en) * | 2023-01-30 | 2024-08-08 | 5Metis, Inc. | Boron containing compounds and their uses |
| WO2024209717A1 (ja) | 2023-04-06 | 2024-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN116396222A (zh) * | 2023-04-10 | 2023-07-07 | 上海睿腾医药科技有限公司 | 一种康奈非尼中间体1-（3-氨基-1-异丙基-1h-吡唑-4-基）乙-1-酮的合成方法 |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4104250A (en) * | 1976-08-11 | 1978-08-01 | Borg-Warner Corporation | Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents |
| JPS5475888A (en) | 1977-11-29 | 1979-06-18 | Jiyasuko Kk | Surgical laser |
| DE3571974D1 (en) | 1984-12-06 | 1989-09-07 | Pfizer | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| AU7106996A (en) | 1995-09-07 | 1997-03-27 | Fuisz Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| EP0910401A1 (en) | 1996-05-23 | 1999-04-28 | Applied Research Systems ARS Holdings N.V. | Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| EP1000055A1 (en) | 1997-05-22 | 2000-05-17 | G.D. Searle & Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
| CA2396380C (en) | 1999-12-23 | 2015-04-21 | David Hayes | Improved pharmaceutical compositions for poorly soluble drugs |
| WO2002018654A1 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DK1441714T3 (da) | 2001-10-25 | 2008-03-31 | Novartis Ag | Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor |
| US7247734B2 (en) | 2001-12-21 | 2007-07-24 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
| TWI338685B (en) | 2002-03-13 | 2011-03-11 | Array Biopharma Inc | N3 alkylated benzimid azole derivatives as mek inhibitors |
| MXPA06003163A (es) | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| DK1692113T3 (en) | 2003-11-14 | 2018-01-08 | Lorus Therapeutics Inc | ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES |
| WO2005068452A1 (en) | 2004-01-09 | 2005-07-28 | Novartis Ag | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors |
| TW200610762A (en) | 2004-06-10 | 2006-04-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| JP2008533172A (ja) | 2005-03-17 | 2008-08-21 | ノバルティス アクチエンゲゼルシャフト | チロシン／スレオニンキナーゼ阻害剤、特にＢ−ＲＡＦキナーゼ阻害剤としての、Ｎ−［３−（１−アミノ−５，６，７，８−テトラヒドロ−２，４，４ｂ−トリアザフルオレン−９−イル）−フェニル］ベンズアミド |
| US20070099856A1 (en) | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
| JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| MX2008002492A (es) | 2005-08-22 | 2008-04-03 | Novartis Ag | Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante. |
| US20080242667A1 (en) | 2005-08-26 | 2008-10-02 | Smithkline Beecham Corporation | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| JP2009530261A (ja) | 2006-03-16 | 2009-08-27 | ファイザー・プロダクツ・インク | ピラゾール化合物 |
| WO2007115286A2 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| US7501430B2 (en) * | 2006-04-17 | 2009-03-10 | Arqule, Inc. | RAF inhibitors and their uses |
| WO2008033747A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| US8877764B2 (en) | 2006-09-18 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| MX2009003456A (es) | 2006-10-02 | 2009-04-14 | Irm Llc | Compuestos y composiciones como inhibidores de proteina cinasa. |
| AU2007308045A1 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| JP4792126B2 (ja) * | 2007-08-01 | 2011-10-12 | ファイザー・インク | ピラゾール化合物およびＲａｆ阻害剤としてのその使用 |
| CN101827584A (zh) | 2007-10-19 | 2010-09-08 | 雅培股份有限两合公司 | N-芳基脲基药物的固态分散体产品 |
| RU2492170C9 (ru) | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2 |
| KR101408517B1 (ko) * | 2008-03-21 | 2014-06-17 | 노파르티스 아게 | 신규한 헤테로시클릭 화합물 및 그의 용도 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| HRP20120577T1 (hr) * | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences S.R.L. | 3,4-diarilpirazoli kao inhibitori proteinskih kinaza |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| EP2350052B1 (en) | 2008-09-29 | 2014-08-13 | Boehringer Ingelheim International GmbH | Antiproliferative compounds |
| PL2346495T5 (pl) | 2008-10-07 | 2024-06-10 | Kudos Pharmaceuticals Limited | Preparat farmaceutyczny 514 |
| US20110293750A1 (en) * | 2008-11-11 | 2011-12-01 | Yale University | Activated wnt-beta-catenin signaling in melanoma |
| JP5490137B2 (ja) * | 2008-12-19 | 2014-05-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害薬としての二環式ピラゾール |
| AR075180A1 (es) | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| RU2402602C1 (ru) | 2009-02-12 | 2010-10-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН |
| WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| ES2570756T3 (es) * | 2009-06-15 | 2016-05-20 | Nerviano Medical Sciences Srl | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| CN102947290B (zh) | 2010-01-27 | 2015-05-27 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| JP5938038B2 (ja) | 2010-08-03 | 2016-06-22 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用 |
| PT2688572T (pt) | 2011-03-21 | 2017-06-02 | Valcuria Ab | Composição farmacêutica com um inibidor de hdac e um esteroide e sua utilização |
| EP2720696B1 (en) | 2011-06-14 | 2016-05-25 | Novartis AG | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| BR112014011223A8 (pt) | 2011-11-11 | 2023-01-31 | Novartis Ag | Método de tratar uma doença proliferativa |
| MX353446B (es) | 2011-11-23 | 2018-01-12 | Novartis Ag | Formulaciones farmaceuticas. |
| CA2890663A1 (en) | 2012-11-08 | 2014-05-15 | Novartis Ag | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| US10576680B2 (en) | 2015-11-19 | 2020-03-03 | The Boeing Company | Modular thermoforming system |
-
2010
- 2010-08-26 AR ARP100103123A patent/AR077975A1/es active IP Right Grant
- 2010-08-26 JO JOP/2010/0297A patent/JO3002B1/ar active
- 2010-08-27 PT PT107482119T patent/PT2470526E/pt unknown
- 2010-08-27 DK DK10748211.9T patent/DK2470526T3/da active
- 2010-08-27 WO PCT/US2010/046930 patent/WO2011025927A1/en not_active Ceased
- 2010-08-27 UY UY0001032860A patent/UY32860A/es active IP Right Grant
- 2010-08-27 RS RS20170017A patent/RS55568B1/sr unknown
- 2010-08-27 HU HUE14152945A patent/HUE032847T2/hu unknown
- 2010-08-27 PT PT141529453T patent/PT2727918T/pt unknown
- 2010-08-27 NZ NZ598924A patent/NZ598924A/xx unknown
- 2010-08-27 UA UAA201203042A patent/UA112285C2/uk unknown
- 2010-08-27 CU CU2012000034A patent/CU24110B1/es active IP Right Grant
- 2010-08-27 SI SI201031371A patent/SI2727918T1/sl unknown
- 2010-08-27 HR HRP20140799AT patent/HRP20140799T1/hr unknown
- 2010-08-27 BR BR112012004453-2A patent/BR112012004453B1/pt active IP Right Grant
- 2010-08-27 RS RS20140430A patent/RS53489B1/sr unknown
- 2010-08-27 CA CA2771775A patent/CA2771775C/en active Active
- 2010-08-27 EA EA201500175A patent/EA201500175A1/ru unknown
- 2010-08-27 SG SG2012009304A patent/SG178351A1/en unknown
- 2010-08-27 EA EA201200373A patent/EA025222B1/ru not_active IP Right Cessation
- 2010-08-27 EP EP14152945.3A patent/EP2727918B1/en active Active
- 2010-08-27 PL PL10748211T patent/PL2470526T3/pl unknown
- 2010-08-27 GE GEAP201012645A patent/GEP20146102B/en unknown
- 2010-08-27 DK DK14152945.3T patent/DK2727918T3/da active
- 2010-08-27 ES ES10748211.9T patent/ES2492499T3/es active Active
- 2010-08-27 ME MEP-2017-6A patent/ME02684B/me unknown
- 2010-08-27 ES ES14152945.3T patent/ES2610825T3/es active Active
- 2010-08-27 SI SI201030711T patent/SI2470526T1/sl unknown
- 2010-08-27 PL PL14152945T patent/PL2727918T3/pl unknown
- 2010-08-27 LT LTEP14152945.3T patent/LT2727918T/lt unknown
- 2010-08-27 AU AU2010286569A patent/AU2010286569C1/en active Active
- 2010-08-27 PE PE2012000268A patent/PE20120861A1/es active IP Right Grant
- 2010-08-27 JP JP2012527014A patent/JP5475888B2/ja active Active
- 2010-08-27 MX MX2012002546A patent/MX2012002546A/es active IP Right Grant
- 2010-08-27 CN CN201080038197.8A patent/CN102725283B/zh active Active
- 2010-08-27 CN CN201410040923.XA patent/CN103896921B/zh active Active
- 2010-08-27 SM SM20170036T patent/SMT201700036T1/it unknown
- 2010-08-27 ME MEP-2014-94A patent/ME01860B/me unknown
- 2010-08-27 MY MYPI2012000611A patent/MY156259A/en unknown
- 2010-08-27 EP EP10748211.9A patent/EP2470526B1/en active Active
- 2010-08-27 IN IN2469DEN2012 patent/IN2012DN02469A/en unknown
- 2010-08-27 KR KR1020127007860A patent/KR101413392B1/ko active Active
- 2010-08-27 SG SG10201405311TA patent/SG10201405311TA/en unknown
- 2010-08-27 US US12/870,130 patent/US8501758B2/en not_active Ceased
-
2012
- 2012-02-09 CL CL2012000340A patent/CL2012000340A1/es unknown
- 2012-02-13 IL IL218084A patent/IL218084A/en active IP Right Grant
- 2012-02-17 TN TNP2012000081A patent/TN2012000081A1/en unknown
- 2012-02-24 NI NI201200029A patent/NI201200029A/es unknown
- 2012-02-24 CO CO12032570A patent/CO6612222A2/es active IP Right Grant
- 2012-02-24 DO DO2012000051A patent/DOP2012000051A/es unknown
- 2012-02-27 HN HN2012000441A patent/HN2012000441A/es unknown
- 2012-02-27 GT GT201200053A patent/GT201200053A/es unknown
- 2012-02-28 EC ECSP12011700 patent/ECSP12011700A/es unknown
- 2012-02-28 CR CR20120102A patent/CR20120102A/es unknown
- 2012-03-19 ZA ZA2012/02020A patent/ZA201202020B/en unknown
- 2012-03-23 MA MA34716A patent/MA33604B1/fr unknown
-
2013
- 2013-06-28 US US13/931,111 patent/US9314464B2/en active Active
-
2014
- 2014-02-06 JP JP2014021339A patent/JP6045519B2/ja active Active
- 2014-09-12 SM SM201400133T patent/SMT201400133B/xx unknown
-
2016
- 2016-01-13 US US14/994,827 patent/US9593100B2/en active Active
- 2016-01-13 US US14/994,710 patent/US9593099B2/en active Active
- 2016-03-15 US US15/070,905 patent/US10005761B2/en active Active
- 2016-06-10 US US15/179,644 patent/US9850230B2/en active Active
- 2016-06-10 US US15/179,385 patent/US9850229B2/en active Active
-
2017
- 2017-01-03 HR HRP20170005TT patent/HRP20170005T1/hr unknown
- 2017-01-10 CY CY20171100028T patent/CY1118452T1/el unknown
- 2017-01-19 SM SM201700036T patent/SMT201700036B/it unknown
- 2017-11-20 US US15/818,264 patent/US10568884B2/en active Active
- 2017-11-20 US US15/818,082 patent/US10576080B2/en active Active
-
2019
- 2019-02-12 LU LU00101C patent/LUC00101I2/fr unknown
- 2019-02-12 LU LU00102C patent/LUC00102I2/fr unknown
- 2019-03-01 HU HUS1900013C patent/HUS1900013I1/hu unknown
- 2019-03-01 HU HUS1900012C patent/HUS1900012I1/hu unknown
- 2019-03-05 NO NO2019011C patent/NO2019011I1/no unknown
- 2019-03-05 NO NO2019012C patent/NO2019012I1/no unknown
- 2019-03-07 LT LTPA2019006C patent/LTPA2019006I1/lt unknown
- 2019-03-07 LT LTPA2019005C patent/LTC2470526I2/lt unknown
- 2019-03-15 NL NL300973C patent/NL300973I2/nl unknown
- 2019-03-18 CY CY2019013C patent/CY2019013I1/el unknown
- 2019-03-18 CY CY2019014C patent/CY2019014I1/el unknown
-
2020
- 2020-01-14 US US16/741,937 patent/US20200323852A1/en not_active Abandoned
-
2021
- 2021-07-15 US US17/376,199 patent/USRE49556E1/en active Active
-
2022
- 2022-04-20 US US17/724,589 patent/US20230116233A1/en not_active Abandoned
-
2023
- 2023-01-27 EC ECSENADI20234573A patent/ECSP23004573A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20146102B (en) | Compounds and compositions as protein kinase inhibitors | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| GEP201706703B (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
| MY153915A (en) | Organic compounds | |
| MX2009000884A (es) | Derivados de piridizinona. | |
| GEP20166484B (en) | Protein kinase inhibitors | |
| GEP20156242B (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| MY160454A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
| MX2010001754A (es) | Derivados de azepina como inhibidores de gamma secretasa. | |
| GEP201606598B (en) | Heteroaromatic compounds as dopamine d1 ligands | |
| GEP20135912B (en) | 1-benzyl-3- hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression | |
| GEP20125511B (en) | Mapk/erk kinase inhibitors | |
| MX2010010406A (es) | Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina. | |
| MY161461A (en) | Akt and p70 s6 kinase inhibitors | |
| EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| TW200745004A (en) | Novel compounds, their preparation and use | |
| GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
| GEP20135913B (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression | |
| SG158091A1 (en) | Imidazoazepinone compounds |